Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers

被引:7
作者
Woodcock, Eric A. [1 ,2 ]
Lundahl, Leslie H. [1 ]
Greenwald, Mark K. [1 ,2 ,3 ]
机构
[1] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA
[2] Wayne State Univ, Translat Neurosci Program, Detroit, MI 48201 USA
[3] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharm Practice, Detroit, MI 48201 USA
关键词
Buprenorphine; Maintenance; Dose taper; Heroin; Abstinence; Relapse; DRUG; METHADONE; TRIAL; REINFORCEMENT; MULTICENTER; WITHDRAWAL; ADDICTION; ATTRITION; NALOXONE; DURATION;
D O I
10.1016/j.drugalcdep.2014.11.016
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Buprenorphine (BUP) is effective for treating opioid use disorder. Individuals' heroin-use characteristics may predict their responses to BUP, which could differ during maintenance and dose-taper phases. If so, treatment providers could use pre-treatment characteristics to personalize level of individual care and possibly improve treatment outcomes. Methods: Non-treatment-seeking heroin-dependent volunteers (N = 34) initiated outpatient BUP maintenance (8-mg/day) and submitted urine samples thrice weekly tested for opioids (non-contingent result). After completing three programmatically-related inpatient behavioral pharmacology experiments (while maintained on 8-mg/day BUP), participants were discharged and underwent a double-blind BUP dose taper (4-mg/day, 2-mg/day and 0-mg/day during weeks 1-3, respectively) with an opioid-abstinence incentive ($30 per consecutive opioid-negative urine specimen, obtained thrice weekly). Results: Participants who reported less pre-study (past-month) heroin use and shorter lifetime duration of heroin use were more likely to submit an opioid-negative urine sample during initial outpatient BUP maintenance. Participants who reported more lifetime heroin-quit attempts and provided any opioid-free urine sample during initial outpatient maintenance sustained longer continuous opioid-abstinence during the BUP dose taper. Participants who reported >3 lifetime quit attempts abstained from opioid use nearly one week longer (14 days vs. 8 days to opioid-lapse) and nearly half (46.7%) refrained from opioid use during dose taper. Conclusions: Number of prior heroin quit attempts may predict BUP dose taper response and provide a metric for stratifying heroin-dependent individuals by relative risk for opioid lapse. This metric may inform personalized relapse prevention care and improve treatment outcomes. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:89 / 96
页数:8
相关论文
共 44 条
  • [1] A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence
    Alterman, AI
    Kampman, K
    Boardman, CR
    Cacciola, JS
    Rutherford, MJ
    McKay, JR
    Maany, I
    [J]. DRUG AND ALCOHOL DEPENDENCE, 1997, 46 (1-2) : 79 - 85
  • [2] ALTERNATE-DAY DOSING DURING BUPRENORPHINE TREATMENT OF OPIOID DEPENDENCE
    AMASS, L
    BICKEL, WK
    HIGGINS, ST
    BADGER, GJ
    [J]. LIFE SCIENCES, 1994, 54 (17) : 1215 - 1228
  • [3] [Anonymous], 2013, WORLD DRUG REP 2013
  • [4] [Anonymous], J SUBSTANCE USE
  • [5] Becker AB, 2001, AM J ADDICTION, V10, P111
  • [6] Utility of lead-in period in cocaine dependence pharmacotherapy trials
    Bisaga, A
    Aharonovich, E
    Garawi, F
    Levin, FR
    Rubin, E
    Raby, WN
    Vosburg, SK
    Nunes, EV
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2005, 77 (01) : 7 - 11
  • [7] CARROLL KM, 1992, ARCH GEN PSYCHIAT, V49, P464
  • [8] Cohen J., 2013, Statistical power analysis for the behavioral sciences
  • [9] Mechanisms of opioid-induced pain and antinociceptive tolerance: signal transduction
    Colpaert, FC
    [J]. PAIN, 2002, 95 (03) : 287 - 288
  • [10] The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review
    Dunn, Kelly E.
    Sigmon, Stacey C.
    Strain, Eric C.
    Heil, Sarah H.
    Higgins, Stephen T.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2011, 119 (1-2) : 1 - 9